ITGAV/ITGB8
(Integrin alpha V beta 8 (ITGAV/ITGB8))
Type de proteíne
Recombinant
Activité biologique
Active
Attributs du protein
AA 31-992
Origine
Humain
Source
HEK-293 Cells
Purification/Conjugué
Cette ITGAV/ITGB8 protéine est marqué à la His tag.
Application
Functional Studies (Func)
Séquence
AA 31-992
Attributs du produit
Human ITGAV & ITGB8 Heterodimer Protein, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 113 kDa (ITGAV) and 75.5 kDa (ITGB8). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic tail and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The reducing (R) protein migrates as 145 kDa (ITGAV) and 100-116 kDa (ITGB8) respectively due to glycosylation.
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.